At Medlior we collaborate with highly-qualified medical professionals to support, and inform, a wide range of clinical and therapeutic research topics. As part of our “Expert Angle” news page we are pleased to present our first interview with Dr. Carlos Fernandez, Founding Principal of CRF Consulting, and a Strategic Advisor and member of Medlior’s Global Research Team.
For the first time in history, Canada’s aging population now outnumbers children. With the increasing elderly population, geriatric care is becoming a vital area of therapeutic medicine and health research. Dr. Fernandez, provides an in-depth knowledge in geriatrics and neuropharmacology to the Medlior team. Continue reading to learn more about his expertise.
Dr. Fernandez is a clinical consultant with a broad background in neuroscience and geriatrics, with specialized expertise in Alzheimer’s disease and related disorders, psychiatry, clinical pharmacology, sleep disorders, and neuropsychopharmacology. Prior roles have included 14 years in academia, 7 years in industry as a Medical Science Liaison, over 20 years of advance clinical experience, and 3 years as a health outcomes research consultant. Not only does Carlos’ experience bring valuable insight to clinical medicine, but his extensive background in quantitative research and psychometrics provides him with the ability to disseminate health research accurately for industry, academic, and clinical audiences.
Dr. Fernandez’s path to becoming a real-world evidence (RWE) and health outcomes research consultant started in pharmacy. As a pharmacist, Carlos discovered he was drawn to cardiovascular medicine. During his fellowship in geriatrics he began to further explore cardiovascular medicine and realized there was an untapped need for research using real world data from a clinical pharmacology perspective.
An example of how Dr. Fernandez has integrated clinical pharmacology expertise with RWE to optimize outcomes for patients is reflected in his research paper on the suboptimal use of Warfarin, an oral anticoagulant, in long term care facilities.(Rojas-Fernandez, 2017 #1) According to Dr. Rojas-Fernandez’s research, Warfarin has been used for more than five decades. However, Warfarin’s utility and safety in elderly patients remains suboptimal, and has been identified as one of the top three drugs leading to preventable hospital admissions in older patients. However, there is a lack of contemporary research insight into oral anticoagulant use and management in long term care facilities.
What this means for the bigger picture of long term care is examining how we make decisions about healthcare treatment plans in a real world setting, and if there is space to make it better. Working with consultants such as Dr. Fernandez, Medlior can tap into varied expertise, research programs and medical data which you may not otherwise have access to.
Furthermore, the Canadian provincial healthcare systems are set up in such a way that they promote the collection and organization of de-identified patient data. As it exists now, an abundant volume of data are collected, but often not utilized for research. These data resources may be accessed by Medlior, providing our clients with access to a wealth of information to provide insights into treatment patterns and clinical outcomes not examined in real-world settings. In addition, by utilizing RWE, researchers can explore burden of disease in populations not often included in clinical trial designs, such as older people to understand unmet need and areas for improvement in patient care. Ultimately, the goal of RWE should be to assist and support medical practitioners by helping them further understand patient characteristics associated with specific clinical outcomes, in a real-world settings.
Contact Medlior today to see how our team of experts can help yours.